{"id":"NCT02431702","sponsor":"Janssen Scientific Affairs, LLC","briefTitle":"A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform","officialTitle":"A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-07-08","primaryCompletion":"2019-11-12","completion":"2019-11-12","firstPosted":"2015-05-01","resultsPosted":"2021-01-19","lastUpdate":"2025-04-29"},"enrollment":337,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia","Psychotic Disorders"],"interventions":[{"type":"DRUG","name":"Aripiprazole","otherNames":[]},{"type":"DRUG","name":"Haloperidol","otherNames":[]},{"type":"DRUG","name":"Olanzapine","otherNames":[]},{"type":"DRUG","name":"Oral Paliperidone ER","otherNames":[]},{"type":"DRUG","name":"Perphenazine","otherNames":[]},{"type":"DRUG","name":"Quetiapine","otherNames":[]},{"type":"DRUG","name":"Oral Risperidone","otherNames":[]},{"type":"DRUG","name":"Paliperidone Palmitate Injection (PP1M)","otherNames":[]},{"type":"DRUG","name":"Paliperidone Palmitate Injection (PP3M)","otherNames":[]}],"arms":[{"label":"Part-1: Oral Antipsychotics (OAP)","type":"ACTIVE_COMPARATOR"},{"label":"Part-2: Paliperidone Palmitate (PP)","type":"EXPERIMENTAL"},{"label":"Part-2: OAP","type":"ACTIVE_COMPARATOR"},{"label":"Part-3: PP - PP","type":"EXPERIMENTAL"},{"label":"Part-3: OAP - Delayed Start Paliperidone Palmitate (PP)","type":"EXPERIMENTAL"},{"label":"Part-3: OAP - OAP","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study is to compare effectiveness of paliperidone palmitate (PP: paliperidone palmitate once-monthly and 3-month injections) versus oral antipsychotic (OAP \\[that is oral paliperidone extended release {ER}, oral risperidone, or another OAP\\]) in delaying time to treatment failure. The study will also evaluate changes in cognition, functioning, brain intracortical myelin (ICM) volume following treatment with PP compared with OAP in participants with recent-onset schizophrenia or schizophreniform disorder.","primaryOutcome":{"measure":"Part-2 (Disease Progression): Time to First Treatment Failure","timeFrame":"From Day 1 up to 9 Months","effectByArm":[{"arm":"Part-2: Paliperidone Palmitate (PP)","deltaMin":null,"sd":null},{"arm":"Part-2: OAP","deltaMin":null,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":38,"countries":["United States","Brazil","Mexico"]},"refs":{"pmids":["37756123","37004331","35939921","35247794"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":273},"commonTop":["Weight Increased","Headache","Insomnia","Somnolence","Nausea"]}}